IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
-3.03%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$705M
AUM Growth
+$705M
(-7.5%)
Cap. Flow
-$3.36M
Cap. Flow
% of AUM
-0.48%
Top 10 Holdings %
Top 10 Hldgs %
36.96%
Holding
95
New
21
Increased
24
Reduced
14
Closed
29
Top Buys
| 1 |
Tenet Healthcare
THC
|
$20.3M |
| 2 |
Amgen
AMGN
|
$17.5M |
| 3 |
Medtronic
MDT
|
$17.2M |
| 4 |
Becton Dickinson
BDX
|
$16.8M |
| 5 |
DexCom
DXCM
|
$16.3M |
Top Sells
| 1 |
Cigna
CI
|
$34.3M |
| 2 |
Zimmer Biomet
ZBH
|
$25.8M |
| 3 |
Centene
CNC
|
$13.5M |
| 4 |
AbbVie
ABBV
|
$13.5M |
| 5 |
Schrodinger
SDGR
|
$13.2M |
Sector Composition
| 1 | Healthcare | 99.61% |
| 2 | Consumer Discretionary | 0.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Tenet Healthcare
THC
$16.3B
| $35.6M | 4.93% | 540,000 +308,000 | +133% | +$20.3M |
|
2
argenx
ARGX
$43.6B
| $34.4M | 4.76% | 70,000 +30,000 | +75% | +$14.7M |
|
3
Boston Scientific
BSX
$156B
| $29M | 4.02% | 550,000 +84,000 | +18% | +$4.44M |
|
4
MoonLake Immunotherapeutics
MLTX
$3.54B
| $28.5M | 3.95% | 500,000 +200,000 | +67% | +$11.4M |
|
5
Cytokinetics
CYTK
$4.23B
| $23.6M | 3.26% | 800,000 +150,000 | +23% | +$4.42M |
|
|
6
Medtronic
MDT
$119B
| $23.5M | 3.25% | 300,000 +220,000 | +275% | +$17.2M |
|
|
NARI
7
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $22.9M | 3.17% | 350,000 +195,000 | +126% | +$12.8M |
|
8
McKesson
MCK
$85.4B
| $21.7M | 3.01% | 50,000 -22,000 | -31% | -$9.57M |
|
9
Inspire Medical Systems
INSP
$2.77B
| $20.8M | 2.88% | 105,000 +2,000 | +2% | +$397K |
|
10
Novartis
NVS
$245B
| $20.4M | 2.82% | 200,000 +97,000 | +94% | +$9.88M |
|
11
Cencora
COR
$56.5B
| $19.8M | 2.74% | 110,000 +84,000 | +323% | +$15.1M |
|
|
12
Amgen
AMGN
$155B
| $17.5M | 2.42% | +65,000 | New | +$17.5M |
|
|
13
Cigna
CI
$80.3B
| $17.2M | 2.38% | 60,000 -120,000 | -67% | -$34.3M |
|
|
14
Becton Dickinson
BDX
$55.3B
| $16.8M | 2.33% | +65,000 | New | +$16.8M |
|
15
Encompass Health
EHC
$12.3B
| $16.8M | 2.32% | 250,000 +30,000 | +14% | +$2.01M |
|
|
16
DexCom
DXCM
$29.5B
| $16.3M | 2.26% | +175,000 | New | +$16.3M |
|
17
Ventyx Biosciences
VTYX
$171M
| $14.9M | 2.07% | 430,000 +80,000 | +23% | +$2.78M |
|
18
Revolution Medicines
RVMD
$7.1B
| $14.5M | 2.01% | 525,000 +169,000 | +47% | +$4.68M |
|
19
Eli Lilly
LLY
$657B
| $13.4M | 1.86% | 25,000 -5,000 | -17% | -$2.69M |
|
20
CRISPR Therapeutics
CRSP
$4.71B
| $12.5M | 1.73% | 275,000 +175,000 | +175% | +$7.94M |
|
21
Molina Healthcare
MOH
$9.8B
| $11.5M | 1.59% | +35,000 | New | +$11.5M |
|
22
Teladoc Health
TDOC
$1.37B
| $11.2M | 1.54% | 600,000 +400,000 | +200% | +$7.44M |
|
23
Revvity
RVTY
$10.5B
| $11.1M | 1.53% | 100,000 -40,000 | -29% | -$4.43M |
|
24
Avantor
AVTR
$9.18B
| $11.1M | 1.53% | +525,000 | New | +$11.1M |
|
25
Elevance Health
ELV
$71.8B
| $10.9M | 1.51% | 25,000 -5,000 | -17% | -$2.18M |
|